

## TREATMENT FORM



**INSTRUCTIONS** 

To be completed in full, signed, and dated, then faxed to 844-394-7155. For additional assistance, call 84-INGREZZA (844-647-3992), 8  $_{\rm AM}$  – 8  $_{\rm PM}$  EST, M – F.

1) PATIENT INFORMATION					
First Name*: Last Name*:			Last 4 digits of the SSN:		Date of Birth*: / /
Address:		City:		State:	ZIP:
Preferred Phone:		US Resident:	☐ Yes ☐ No	Gender:	Male
Is Preferred Phone a mobile number?   Yes	Email:				
Alternate Contact/Care Partner Name:	Alternate Contact/Care Partner Phone:				
Patient Residence: At Home LTC Grou	p Home	al) I consent to ha	ve my prescription s	hipped to: 🔲 🤇	Care Partner   HCP Offic
Patient/Authorized Representative Signature:				Date:	
By signing here, I authorize the use and disclosu PHI as set forth in the HIPAA Authorization on p		orized Representativ	ve's Authority:	I	
2) PATIENT INSURANCE INFO		ach a copy of th	e patient's insuran	ice card (check	k below if no insurance
Medical Insurance Name:		Prescription Insurance Name:			
Cardholder ID #:	Cardholder ID	Cardholder ID #:			
Policy Holder Name:	BIN#:	PCN#:			
Phone: Policy H	older DOB: / /	Rx Group #:		Phone:	
Payer Type:	☐ Medicaid ☐ Other ☐	stient does not have insurance—please fill out the PAP application instead of this for			
3 CLINICAL INFORMATION					
Primary Diagnosis Code Category*: ☐ Tardive dyskinesia (G24.01) ☐ Huntington's			Other diagnosis	:	Allergies:
4) PRESCRIPTION FOR INGRE					
PRESCRIPTION INSTRUCTIONS*: Check 1 k			enance Rx.		
Initial Rx		Maintenance	e Rx <sup>a</sup>		
40 mg once daily x 7 then 80 mg once da	40 mg or	40 mg once daily, 1-month supply			
40 mg once daily x 14 then 60 mg once d	60 mg once daily, 1-month supply				
No refills.	80 mg once daily, 1-month supply Refills #				
Other Rx Sig:			Oı	ıantity:	Other Rx Refills:
alf in-office samples were used, you may select Maintenan	ce Rx only.		40	.urreity	other fortems
Preferred Pharmacy			] FAINTHERX Rate		not required if a prescription ens Community-Based Specialty
or applicable: ☐ CVS Specialty Pharma	cy	ns Pharmacy <sup>b</sup> □	No preference		contact the store directly.
Local pharmacy with	Pha	armacy NPI:	Pharmacy	<sup>,</sup> Fax:	
Pharmacy Phone:					
5 PRESCRIBER INFORMATION	V				
Prescriber Name*:		Preso	criber NPI*:		
Facility Name:			Phor	ne:	Fax:
Address:	City:		State	:	ZIP:
Office/Facility Contact Name:	Phone:	Fax:	Emai	l:	
6 PRESCRIBER CERTIFICATIO	N				
I certify that the information provided in this INGREZZA®	(valbenazine) capsules Treatment Fo		curate to the best of my k federal and/or state law, l		

I certify that the information provided in this INGREZZA® (valbenazine) capsules Treatment Form is complete and accurate to the best of my knowledge, I have prescribed INGREZZA based on my judgment of medical necessity, and I will supervise the patient's medical treatment. I certify that, where required by federal and/or state law, I have obtained my patient's written legal permission to share identifiable information with Neurocrine Biosciences, Inc., its agents, and pharmacies, including but not limited to the INBRACE Support Program Pharmacy and the pharmacies listed in Section 4 above. I authorize the forwarding of this prescription and information to a dispensing specialty pharmacy. If the patient has requested shipment to my office, LTC facility, or pharmacy, I agree not to receive any compensation for dispensing the product, and I will clearly label and dispense only for use by the patient.

Prescriber Signature: \* Date\*:

(Original signature required—If required by applicable law, please attach copies of all prescriptions on official state prescription forms)

\*Indicates required fields.





## TREATMENT FORM



## PATIENT HIPAA AUTHORIZATION FOR USE AND DISCLOSURE OF PROTECTED HEALTH INFORMATION

I authorize Neurocrine, companies working with Neurocrine, and my healthcare provider, pharmacy, and insurer to use and disclose to Neurocrine, and companies working with Neurocrine, my Protected Health Information ("PHI"), such as information provided on this form, my prescription, insurance, medical therapy information and other PHI for the following purposes: (1) providing financial assistance options, (2) reimbursement support, (3) medication compliance and persistence, (4) information about Neurocrine products and programs, which may from time to time include requests to participate in market research or other initiatives related to my healthcare experiences, and (5) other treatment-related services, including providing information and materials related to the INBRACE Support Program (collectively called "Support Services"). I understand that the companies working with Neurocrine, including my pharmacy, may receive payment related to the use and disclosure of my PHI which could be considered marketing under HIPAA, in which case I hereby provide my authorization for such arrangement. I understand that once my PHI is disclosed to Neurocrine or companies working with Neurocrine it will no longer be protected by HIPAA and may be subject to redisclosure by the recipient. I understand that this authorization shall continue in effect for a period of ten years, unless a one-year period is required by law. I understand that I may revoke this authorization by contacting an INBRACE Support Program representative by telephone (844-647-3992) or by mailing a letter to Neurocrine, Attn: INBRACE Support Program, 200 Industry Dr, Suite 100, Pittsburgh, PA 15275. I understand that cancelling this authorization will not affect any use or disclosure of my PHI that has already taken place in reliance on this authorization. I understand that I am not required to sign this authorization and that my healthcare providers will not otherwise condition my treatment, payment, health insurance enrollment, or eligibility for health care benefits to which I am otherwise entitled on whether I sign this authorization. However, if I choose not to sign, Neurocrine will not be able to help me with Support Services as described above. I may obtain a copy of this authorization upon request.

For more on how Neurocrine uses your information, please visit www.neurocrine.com/privacy-policy

